This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lister, P. D.
Right arrow Articles by Sanders, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lister, P. D.
Right arrow Articles by Sanders, C. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1999, p. 882-889, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Clavulanate Induces Expression of the Pseudomonas aeruginosa AmpC Cephalosporinase at Physiologically Relevant Concentrations and Antagonizes the Antibacterial Activity of Ticarcillin

Philip D. Lister,* Victoria M. Gardner, and Christine C. Sanders

Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178

Received 10 August 1998/Returned for modification 3 December 1998/Accepted 31 January 1999

Although previous studies have indicated that clavulanate may induce AmpC expression in isolates of Pseudomonas aeruginosa, the impact of this inducer activity on the antibacterial activity of ticarcillin at clinically relevant concentrations has not been investigated. Therefore, a study was designed to determine if the inducer activity of clavulanate was associated with in vitro antagonism of ticarcillin at pharmacokinetically relevant concentrations. By the disk approximation methodology, clavulanate induction of AmpC expression was observed with 8 of 10 clinical isolates of P. aeruginosa. Quantitative studies demonstrated a significant induction of AmpC when clavulanate-inducible strains were exposed to the peak concentrations of clavulanate achieved in human serum with the 3.2- and 3.1-g doses of ticarcillin-clavulanate. In studies with three clavulanate-inducible strains in an in vitro pharmacodynamic model, antagonism of the bactericidal effect of ticarcillin was observed in some tests with regimens simulating a 3.1-g dose of ticarcillin-clavulanate and in all tests with regimens simulating a 3.2-g dose of ticarcillin-clavulanate. No antagonism was observed in studies with two clavulanate-noninducible strains. In contrast to clavulanate, tazobactam failed to induce AmpC expression in any strains, and the pharmacodynamics of piperacillin-tazobactam were somewhat enhanced over those of piperacillin alone against all strains studied. Overall, the data collected from the pharmacodynamic model suggested that induction per se was not always associated with reduced killing but that a certain minimal level of induction by clavulanate was required before antagonism of the antibacterial activity of its companion drug occurred. Nevertheless, since clinically relevant concentrations of clavulanate can antagonize the bactericidal activity of ticarcillin, the combination of ticarcillin-clavulanate should be avoided when selecting an antipseudomonal beta -lactam for the treatment of P. aeruginosa infections, particularly in immunocompromised patients. For piperacillin-tazobactam, induction is not an issue in the context of treating this pathogen.

* Corresponding author. Mailing address: Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178. Phone: (402) 280-1881. Fax: (402) 280-1225. E-mail: pdlister{at}creighton.edu.

Antimicrobial Agents and Chemotherapy, April 1999, p. 882-889, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lister, P. D., Wolter, D. J., Hanson, N. D. (2009). Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms. Clin. Microbiol. Rev. 22: 582-610 [Abstract] [Full Text]  
  • Wolter, D. J., Black, J. A., Lister, P. D., Hanson, N. D. (2009). Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype. J Antimicrob Chemother 64: 294-300 [Abstract] [Full Text]  
  • Jacoby, G. A. (2009). AmpC {beta}-Lactamases. Clin. Microbiol. Rev. 22: 161-182 [Abstract] [Full Text]  
  • Marchiaro, P., Ballerini, V., Spalding, T., Cera, G., Mussi, M. A., Moran-Barrio, J., Vila, A. J., Viale, A. M., Limansky, A. S. (2008). A convenient microbiological assay employing cell-free extracts for the rapid characterization of Gram-negative carbapenemase producers. J Antimicrob Chemother 62: 336-344 [Abstract] [Full Text]  
  • Wolter, D. J., Schmidtke, A. J., Hanson, N. D., Lister, P. D. (2007). Increased Expression of ampC in Pseudomonas aeruginosa Mutants Selected with Ciprofloxacin. Antimicrob. Agents Chemother. 51: 2997-3000 [Abstract] [Full Text]  
  • Dunne, W. M. Jr., Hardin, D. J. (2005). Use of Several Inducer and Substrate Antibiotic Combinations in a Disk Approximation Assay Format To Screen for AmpC Induction in Patient Isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp.. J. Clin. Microbiol. 43: 5945-5949 [Abstract] [Full Text]  
  • Li, C., Nicolau, D. P., Lister, P. D., Quintiliani, R., Nightingale, C. H. (2004). Pharmacodynamic study of {beta}-lactams alone and in combination with {beta}-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible {beta}-lactamase. J Antimicrob Chemother 53: 297-304 [Abstract] [Full Text]  
  • Karlowsky, J. A., Weaver, M. K., Thornsberry, C., Dowzicky, M. J., Jones, M. E., Sahm, D. F. (2003). Comparison of Four Antimicrobial Susceptibility Testing Methods To Determine the In Vitro Activities of Piperacillin and Piperacillin-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J. Clin. Microbiol. 41: 3339-3343 [Abstract] [Full Text]  
  • Wang, H., Kelkar, S., Wu, W., Chen, M., Quinn, J. P. (2003). Clinical Isolates of Enterobacteriaceae Producing Extended-Spectrum {beta}-Lactamases: Prevalence of CTX-M-3 at a Hospital in China. Antimicrob. Agents Chemother. 47: 790-793 [Abstract] [Full Text]  
  • Lee, N. L. S., Yuen, K. Y., Kumana, C. R. (2001). {beta}-Lactam Antibiotic and {beta}-Lactamase Inhibitor Combinations. JAMA 285: 386-388 [Full Text]  
  • Mimoz, O., Leotard, S., Jacolot, A., Padoin, C., Louchahi, K., Petitjean, O., Nordmann, P. (2000). Efficacies of Imipenem, Meropenem, Cefepime, and Ceftazidime in Rats with Experimental Pneumonia Due to a Carbapenem-Hydrolyzing beta -Lactamase-Producing Strain of Enterobacter cloacae. Antimicrob. Agents Chemother. 44: 885-890 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»